Theravance Biopharma (TBPH) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update
February 27, 2023 4:05 PM ESTIncreases capital return program to $325 million from $250 million; as of 2/27/23, approximately $170 million remains in the programDiscontinuing investments in research, reducing headcount by approximately 17%Reports highest quarter of YUPELRI® (revefenacin) net sales and profitability to date; $19.5 million Q4 2022 sales up 27% from Q4 2021 (TBPH implied 35% share)1On track to begin enrollment in ampreloxetine Phase 3 study in Q1 2023Appoints Susannah Gray to Board as new Independent DirectorCommits to declassify the Board of Directors
DUBLIN, Feb. 27, 2023... More
